Updates are available Correction dated 2023-02-06
Click to view Correction: https://doi.org/10.1038/s41586-023-05764-8
Updates are available Correction dated 2023-01-09
Click to view Correction: https://doi.org/10.1038/s41586-022-05631-y
-
Authors
Kee, John
Thudium, Samuel https://orcid.org/0000-0001-6670-3970
Renner, David M. https://orcid.org/0000-0003-0548-3876
Glastad, Karl
Palozola, Katherine
Zhang, Zhen
Li, Yize https://orcid.org/0000-0003-1721-741X
Lan, Yemin
Cesare, Joseph https://orcid.org/0000-0002-5569-1422
Poleshko, Andrey https://orcid.org/0000-0002-6656-2941
Kiseleva, Anna A. https://orcid.org/0000-0002-8720-5062
Truitt, Rachel
Cardenas-Diaz, Fabian L.
Zhang, Xianwen
Xie, Xuping https://orcid.org/0000-0003-0918-016X
Kotton, Darrell N. https://orcid.org/0000-0002-9604-8476
Alysandratos, Konstantinos D.
Epstein, Jonathan A.
Shi, Pei-Yong https://orcid.org/0000-0001-5553-1616
Yang, Wenli https://orcid.org/0000-0002-1873-2336
Morrisey, Edward
Garcia, Benjamin A.
Berger, Shelley L. https://orcid.org/0000-0001-5398-4400
Weiss, Susan R.
Korb, Erica https://orcid.org/0000-0002-7064-8123
- License Information
-
More Information
Article History
Received: 28 December 2020
Accepted: 26 August 2022
First Online: 5 October 2022
Change Date: 6 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-023-05764-8
Change Date: 9 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-022-05631-y
Competing interests
: The laboratory of P.-Y.S. has received funding support in sponsored research agreements from Pfizer, Gilead, Novartis, Merck, GSK, IGM Biosciences and Atea Pharmaceuticals. P.-Y.S. is a member of the scientific advisory boards of AbImmune and is founder of FlaviTech. S.R.W. is on the scientific advisory board of Ocugen and Immunome.
Free to read: This content has been made available to all.
